HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Vertex Pharmaceuticals Announces Advancements of Its Product Suzetrigine for Acute and Neuropathic Pain April 18, 2024 0 Madrigal Pharmaceuticals Announces U.S. Availability of its Newly Approved Product Rezdiffra April 9, 2024 0 Johnson & Johnson to Acquire Shockwave Medical April 5, 2024 0 BioStem Technologies is Releasing its Fourth Quarter 2023 Financial Results Now April 1, 2024 0